This review outlines how clinicians currently diagnose and treat the two main forms of kidney-transplant rejection, T-cell-mediated and antibody-mediated, and underscores that many antibody-mediated rejection treatments still have questionable efficacy, leaving optimized immunosuppression and adherence central to management.